Checkmate_CMP-001-010 - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out how an experimental drug called CMP-001 works with nivolumab in your body and against your cancer.

What is the Condition Being Studied?

Checkmate_CMP-001-010 (Melanoma)

Who Can Participate in the Study?

People who:
- Have received, or are currently receiving, any anti-PD-1 either alone or in combination with other drugs for advanced melanoma, and the cancer has progressed, despite treatment.

Age Group
Adults

What is Involved?

The study has two parts: a screening period and a study dosing period.

If you choose to join the study during the screening period, you will:
- Have physical exams and blood draws
- Have imaging done (CT, MRI, photographs)
- Have a tumor biopsy done

During the study dosing period, you will:
- Receive the study drug(s) directly into your skin/tumor or through an IV
- Return for a follow-up visit 100 days after the last study drug injection
- Have phone calls every 3 months after you finish the study treatment

Study Details

Full Title
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination with Intravenous Nivolumab in Subjects with Refractory Unresectable or Metastatic Melanoma
Principal Investigator
Surgical Oncologist
Protocol Number
IRB: PRO00106865
NCT: NCT04698187
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698